Navigation Links
Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility

Research from Non-clinical Studies Presented at the Targeted Anticancer Therapies (TAT 2007) and the Keystone Symposia Molecular Targets for Cancer Meetings Support Phase 1 Trial Design

SOUTH SAN FRANCISCO, Calif., March 20, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , presented non-clinical data on its development-stage compound, SNS-314, at two leading scientific meetings focused on targeted anticancer medicines. Findings from in vitro and in vivo studies demonstrate that SNS-314 is a selective inhibitor of Aurora kinases with consistently potent anti-tumor activity across a number of cancer types.

"Based on the data presented at TAT 2007 and the Keystone Symposia 'Molecular Targets for Cancer' meetings, we believe that SNS-314 has a compelling preclinical profile and merits full clinical development. In diverse xenograft models, this anticancer agent demonstrates good activity that is linked to mechanistic markers of Aurora inhibition," said Daniel C. Adelman, M.D., Senior Vice President, Research and Development at Sunesis. "The results reported from our non-clinical studies of SNS-314 are impressive, and we are looking forward to starting the Phase 1 dose-escalating clinical study of SNS-314 in patients with advanced solid tumors in the second quarter. In this trial, patients will receive three weekly doses of SNS-314 in a four-week dosing regimen."

In an oral presentation delivered on March 10 at the 5th International Symposium on Targeted Anticancer Therapies (TAT 2007) meeting held in Amsterdam, Sunesis researchers presented results showing SNS-314's anti-tumor activity across a number of cancer models. SNS-314 demonstrated potent and sustained activity in xenograft models of colon, breast, prostate, lung, ovarian and skin cancers, where intermittent dosing caused up to 96 percent tumor growth inhibition. These results suggest that weekly administration may provide an opt
'"/>




Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
... Company to Host Conference Call/Webcast at 8:30 a.m. ... May 28 Alfacell Corporation,(Nasdaq: ACEL ) ... from its confirmatory Phase IIIb clinical trial of ... significance for the,primary endpoint of survival in unresectable ...
Cached Medicine Technology:Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
(Date:7/9/2014)... innovative tool that captures heretofore hidden ways that cells ... protein that makes breast cancer cells more likely to ... cancer,s spread in part by blocking two other proteins ... suggests these two disease processes could have unexpected ties. ... 10 issue of Nature , points to the ...
(Date:7/9/2014)... Center paint a relatively optimistic picture of women,s chances ... spread to the chest wall or skin, but not ... regardless of size and whether they have involved lymph ... called "locally advanced" tumors, suggesting that they are a ... Locally advanced breast cancers of this and other types ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... has been a sharp increase in the number of ... the online, interactive service that allows patients to view ... schedule appointments, and renew prescriptions. , Over a six-year ... each year increased five-fold, while the number of ... to a study by Dr. David Gerber , ...
(Date:7/9/2014)... p>YouTube is for more than watching World Cup highlights, ... of skateboarders landing in unfortunate positions on railings. A ... Dermatology Online Journal shows that YouTube also ... with the public on topics of skin cancer and ... media is the future of how we communicate around ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... a procedure wherein healthy cartilage is transplanted to fix ... OATS procedure) is superior to the standard of care ... such lesions may ultimately help to prevent the onset ... activities reliably. The study by Hospital for Special Surgery ...
... Climate change has impacts on forests, fields, rivers -- and ... these impacts more accurately, a comprehensive comparison of computer-based simulations ... the first time, sectors ranging from ecosystems to agriculture to ... framework. , The models will be provided by more than ...
... HealthDay Reporter , MONDAY, Feb. 6 (HealthDay News) -- Women ... be at increased risk of readmission to a psychiatric hospital ... study suggests. The findings, which appear in the February ... several previous studies showing that women who undergo abortion do ...
... MONDAY, Feb. 6 (HealthDay News) -- Treatment with three ... slightly increased risk of death, a new analysis suggests. ... taken into account by doctors and patients, according to ... analyzed the findings of 10 clinical trials that included ...
... 2012 -- The Fogarty Institute for Innovation announced ... Training Fellowship. This unique, year-long clinical training program ... will provide Fellows with broad exposure to ... emphasis on interventional training. Fellows will also engage ...
... genetics has been peeled back. A team of researchers ... Richard G. Pestell, M.D., PhD., FACP, Director of the KCC ... shown in a study published online Feb. 6 in the Journal ... genetic breakdown known as chromosomal instability (CIN). CIN is a known, ...
Cached Medicine News:Health News:New procedure bests standard of care for fixing damaged cartilage 2Health News:New procedure bests standard of care for fixing damaged cartilage 3Health News:Quantifying climate impacts: New comprehensive model comparison launched 2Health News:Quantifying climate impacts: New comprehensive model comparison launched 3Health News:Does Abortion in First Trimester Raise Risk of Mental Ills' Return? 2Health News:Does Abortion in First Trimester Raise Risk of Mental Ills' Return? 3Health News:Certain Cancer Drugs May Have Fatal Side Effects: Analysis 2Health News:Fogarty Institute for Innovation launches advanced endovascular training fellowship 2Health News:Drugs targeting chromosomal instability may fight a particular breast cancer subtype 2Health News:Drugs targeting chromosomal instability may fight a particular breast cancer subtype 3